WO2006007937A1 - Methods and assays for detecting guanylate cyclase activity - Google Patents
Methods and assays for detecting guanylate cyclase activity Download PDFInfo
- Publication number
- WO2006007937A1 WO2006007937A1 PCT/EP2005/006887 EP2005006887W WO2006007937A1 WO 2006007937 A1 WO2006007937 A1 WO 2006007937A1 EP 2005006887 W EP2005006887 W EP 2005006887W WO 2006007937 A1 WO2006007937 A1 WO 2006007937A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sgc
- cell
- cre
- guanylate cyclase
- vector encoding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Definitions
- the present invention relates to soluble guanylate cyclase (sGC) enzymes. More specifically it provides a cell-based assay system which allows to detect with high efficiency and sensitivity the soluble guanylate cyclase enzymatic activity.
- the invention provides a method of screening molecules that interact with sGC by stimulating or inhibiting its enzymatic activity and that can be used in the diagnosis or therapy of sGC-mediated dysfunctions or diseases.
- the invention further provides gene-constructs, vectors, and cells for use in said method.
- Adenylate cyclases and guanylate cyclases synthesize the intracellular second messengers cAMP and cGMP, respectively, in response to a variety of regulatory signals.
- Mammalian adenylate cyclases are intrinsic plasma membrane proteins that contain a duplicated module consisting of a hexahelical transmembrane region followed by a roughly 40-kDa cytosolic domain (Sunahara, et al. (1996) Annu. Rev. Pharm. Toxicol. 36, 461-480). Highly conserved and homologous sequences within the two cytosolic domains contribute to the active site of the enzyme (Tang, et al. (1995) Science 268, 1769-1772). The x-ray crystal structure of this soluble domain of the enzyme complexed with both activators and inhibitors has also been solved (Tesmer, et al. (1997) Science 278, 1907-1916).
- Guanylate cyclases exist as both soluble and membrane-bound species. Both types of the enzyme contain cytoplasmic domains similar to those of the adenylate cyclases (Garbers, D.L., et al. (1994) MoL Biol. Cell 5, 1-5). Membrane-bound guanylate cyclases are monomers stimulated by the natriuretic peptides, whereas the soluble guanylate cyclase (sGC) exists as a heterodimer consisting of an ⁇ and a ⁇ subunit (both of which are required for catalysis) containing heme as prosthetic group.
- sGC soluble guanylate cyclase
- GC Guanylate cyclase belongs to a family of enzymes which catalyzes the conversion of guanosine 5'- triphosphate (GTP) to cyclic guanosine 3 ', 5'- monophosphate (cGMP).
- GTP guanosine 5'- triphosphate
- cGMP cyclic guanosine 3 ', 5'- monophosphate
- sGC plays an important role in a variety of extracellular signals and different physiological processes, i.e. vasodilatation, platelet aggregation and adhesion and neural transmission.
- the most important physiological activators of sGC are NO and NO-related compounds, which activate the enzyme upon binding to the heme moiety.
- nitric oxide NO
- heme group Binding of nitric oxide (NO) to a prosthetic heme group causes marked activation of soluble guanylate cyclases.
- the pathogenesis of various cardiovascular diseases has been linked to an inappropriate activation of sGC.
- Soluble guanylate cyclase is detectable in organs such as, for example, the heart, lung, liver, kidney, and brain of all mammals, including humans.
- organs such as, for example, the heart, lung, liver, kidney, and brain of all mammals, including humans.
- the oxidation state of the heme group iron in soluble guanylate cyclase may play an essential part.
- a higher proportion of soluble guanylate cyclase with oxidized heme group iron would result in the possibility of diminishing activation of soluble guanylate cyclase by endogenous NO.
- the mutated guanylate cyclase enzyme in particular, has ATP as substrate without having influenced the responsiveness to the respective GC stimulators.
- This mutated form of soluble guanylate cyclase is useful for the detection of Nitric Oxide induced cAMP production.
- Object of the present invention is to provide a cell-based assay useful for the determination of the enzymatic activity of soluble guanylate cyclase (sGC).
- a further object of the invention is the provision of a method of screening molecules that interact with sGC, utilizing said cell-based assay.
- the sGC enzymatic activity is determined by coupling a sGC enzyme with modified substrate specificity to a cAMP sensitive reporter construct in a suitable eukaryotic or prokaryotic cell, whereby the activity of the reporter gene is indicative of the sGC enzymatic activity.
- the sGC enzyme with modified substrate specificity is able to catalyze the conversion of ATP into cyclic AMP without affecting the allosteric regulation of the natural enzyme.
- the sGC substrate specificity can be modified by replacing the amino acid residues involved in nucleotide binding with the corresponding residues present in the active site of adenylate cyclase. For example, when rat sGC is used, the amino acids Arg592 of ⁇ subunit, Glu473 and Cys541 of ⁇ subunit are respectively changed into GIn, Lys and Asp, to confer ATP substrate-specificity. More details on the modification of sGC substrate specificity can be found in Sunahara et al. (1998), which is hereby incorporated by reference.
- the cAMP sensitive reporter construct contains a reporter gene functionally linked to a cAMP-responsive promoter sensitive to intracellular cAMP levels.
- the cAMP-responsive promoter is a MRE/CRE (Multiple Response Element - Ray A, et al. 1989; cAMP Responsive Element: Fink, J. S. et al. 1988) inducible promoter containing from 1 to 4 MREs and from 1 to 5 CRE elements.
- the MRE-CRE inducible promoter sensitive to increased intracellular cAMP levels contains 3 MRE and 5 CRE element repetitions.
- the MREs correspond to the human Interlukin-6 promoter region which enables the cell line to respond to Ga, Gq and Gs signalling (MRE: Ray A,
- Each MRE element is 32 bp and corresponds to the sequence : ATGCT AAAGG ACGTC AC ATTGC AC AATCTTAA.
- TGACGTCA The CRE sequence
- CGTCA conserved sequence motif
- the reporter construct may further contain transcription-regulating elements, selectable markers and viral promoters.
- Suitable reporter genes that may be used according to the invention include, but are not limited to, luciferase, Green Fluorescent Proteins (GFP) and photoprotein genes. This system, however, is very useful not only for reporter gene transcription, but also for the expression and induction of any gene of interest such as the G-protein coupled receptor families (GPCRs), the ion channels and the nuclear hormone receptors.
- GPCRs G-protein coupled receptor families
- the invention in addition provides vectors and host cells containing the sGC-encoding gene and/or the reporter gene construct.
- the host cell is a CHO cell line (hereafter, the CHO cell line containing the described MRE- CRE elements driving the expression of a luciferase reporter gene will be referred to as CHO cAMPL).
- Host cell lines according to the invention are conveniently used as a tool for detection of intracellular NO-release.
- the invention provides a method for determining the sGC enzymatic activity in a cultured eukaryotic or prokaryotic cell, which comprises:
- the invention is directed to a method of identifying molecules that modulate sGC activity, which comprises:
- Molecules that stimulate or inhibit sGC activity can be selected by measuring the reporter gene expression/activity.
- the assay can be carried out in the presence or absence of known NO-releasing substances which activate the enzyme upon NO-binding to its heme moiety.
- NO-releasing molecules and NO-independent sGC activators and inhibitors which are not specific for the catalytic site, e.g. ODQ
- ODQ inhibitors which are not specific for the catalytic site
- the selected compounds represent valuable candidate for the treatment of diseases related to sGC dysfunctions.
- sGC-stimulating compounds can be used in the therapy of diseases involving inappropriate activation of sGC, especially diseases of the cardiovascular system.
- the method of the invention is more advantageous in that a) it does not require radioactive reagents, b) it has a higher sensitivity, c) it can be easily adapted to a high throughput format and d) it is performed in a native environment.
- the invention provides a method of modulating the expression of a gene of interest in cultured eukaryotic or prokaryotic cell, which comprises:
- Rat wild type sGC ⁇ 3 and ⁇ l subunits were amplified from brain cDNA by RT-PCR and used as templates for site directed mutagenesis.
- the amino acids Arg 592 of ⁇ subunit, GIu 473 and Cys 541 of ⁇ subunit were respectively changed into GIn, Lys and Asp, which confer specificity for adenosine.
- Responsive Element Fink, J. S. et al. 1988) inducible promoter at 5' of the luciferase gene of the pMAMneoluc vector (Clontech).
- MRE element 3
- Both vectors were transfected in a stable way in CHO-Kl cells and positive clones were selected on the basis of the best Luciferase induction obtained upon 4 hrs. incubation with the NO donor compound SNAP (Fig. 1).
- the most responsive clone coming from 3 rounds of limiting dilutions was used to test the activity of different compounds such as NO-donors and NO-independent activators, in the presence or absence of the known sGC inhibitor ODQ (Fig. 2-4).
- Luciferase activity was detected after injection of 50 ⁇ l Bright-GloTM (Promega) at the CCD camera (60" measurement, high sensitivity). Published EC 50 1,7x10 "6 M.
- Figure 6 Kinetic and dose response experiments with SNAP 5000 c/w were seeded in 96 wp. 48 h after seeding the cells were incubated with increasing concentration of SNAP: after times of incubation indicated the compound was replaced with medium serum free. Total incubation time 4 h.
- Rat soluble Guanylate Cyclase ( ⁇ 3 and ⁇ l subunits): alpha 3 subunit NM O 17090; coding region: 690 aa long beta 1 subunit NM O 12769; coding region: 619 aa long Rat brain cDNA was purchased from Clontech (cat. N° 637312). 2 ⁇ l of cDNA was used as template in PCR analysis for non quantitative expression analysis. In addition a negative control was performed with no template. Standard PCR procedure were as indicated by Perkin Elmer. PCR protocol was as follows: Primers:
- Primer sGCalpha UP (A) : 5 ' CGGJCTA
- Amplification products were analysed by electrophoresis on 1% agarose gel in IxTAE running buffer following standard procedure, as described by Maniatis et al.
- Mutations into the ⁇ subunit of sGC were inserted by PCR using the wild type gene as template, in particular primers sGCbeta UP and sGCbetaE473K LOW were used to amplify the 5' portion of the gene, primers sGCbetaE473K UP and sGCbetaC541D LOW were used to amplify a central fragment, primers sGCbetaC541D UP and sGCbeta LOW were used to amplify the 3' portion of the gene. To reconstitute the full length mutated gene, these three discrete fragments were used as template in a final PCR reaction performed with primers sGCbeta UP sGCbeta LOW.
- Amplification protocol performed in Perkin Elmer 9700 thermocycler 1 time the following step: pre PCR 2' at 94°C 20 times the following steps: denaturation 30" at 94°C annealing 1 ' at 52 0 C elongation 30" at 68°C
- the mutation R592Q into the ⁇ subunit of sGC was inserted by site directed mutagenesis (QuikChange XL Site-Directed Mutagenesis Kit from Stratagene), using primers sGCalphaR592Q UP and sGCalphaR592Q LOW.
- Amplification protocol performed in Perkin Elmer 9700 thermocycler 1 time the following step: pre PCR 1 ' at 95°C 18 times the following steps: denaturation 30" at 95 0 C annealing 1 ' at 55 0 C elongation 13' at 68 0 C 1 time the following step: elongation 7' at 68°C PCR reaction mix:
- pIRES bi-cistronic mammalian expression vector
- the mutated ⁇ subunit of sGC described above was cloned into EcoRI unique restriction site of pIRES.
- the pIRESsGC ⁇ vector was subsequently digested with Smal to insert the mutated ⁇ subunit of sGC downstream the IRES element. All the constructs obtained were verified by full-length dideoxy sequencing.
- G418 (Calbiochem cod.345812).
- Preculture conditions Cells were seeded for experiments when 70-80% confluent.
- CHO cAMPL previously generated by Axxam, were transfected with pIRESsGC ⁇ mut.
- the stable transfected cells were put in 1st limiting dilution (1st LD) at 1 c/w in 96 wp format.
- the four best responding clones were put in 3rd LD (0.3 c/w, 96 wp format). The final clone was chosen after the 3rd LD selected with SNAP 10 ⁇ M.
- SNAP (Tocris cat# 0598) was dissolved in DMSO at a concentration of 100 mM and stored in aliquots at -20 0 C. Working solution was freshly prepared in Serum Free Medium.
- SIN (Tocris cat# 0 756) was dissolved in water at a concentration of 100 mM and stored in aliquots at -20 0 C.
- NOC18 (Calbiochem cat# 487957) was dissolved in water at a concentration of 100 mM and stored in aliquots at -20 0 C.
- ODQ (Calbiochem cat# 495320) was dissolved in DMSO at a concentration of 100 mM and stored in aliquots at -20 0 C.
- B A Y41-2272 was purchased from Alexis, dissolved in DMSO at a concentration of 10 mM and stored in aliquots at -20 0 C.
- Tyrode Buffer composition NaCl 130 mM, KCl 5 mM, CaCl 2 2 mM, MgCl 2 1 mM, NaHCO 3 5 mM e HEPES 20 mM pH 7.4.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002573357A CA2573357A1 (en) | 2004-07-16 | 2005-06-27 | Methods and assays for detecting guanylate cyclase activity |
JP2007520697A JP2008506371A (en) | 2004-07-16 | 2005-06-27 | Methods and assays for detecting guanylate cyclase activity |
KR1020077000872A KR20070033428A (en) | 2004-07-16 | 2005-06-27 | Methods and assays for detecting guanylate cyclase activity |
AU2005263396A AU2005263396A1 (en) | 2004-07-16 | 2005-06-27 | Methods and assays for detecting guanylate cyclase activity |
IL180666A IL180666A0 (en) | 2004-07-16 | 2007-01-11 | Methods and assays for detecting guanylate cyclase activity |
IS8590A IS8590A (en) | 2004-07-16 | 2007-01-12 | Methods and tests to detect guanylate cyclase activity |
HR20070011A HRP20070011A2 (en) | 2004-07-16 | 2007-01-12 | Methods and assays for detecting guanylate cyclase activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04016774A EP1616965A1 (en) | 2004-07-16 | 2004-07-16 | Methods and assays for detecting guanylate cyclase activity |
EP04016774.4 | 2004-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006007937A1 true WO2006007937A1 (en) | 2006-01-26 |
Family
ID=34925781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/006887 WO2006007937A1 (en) | 2004-07-16 | 2005-06-27 | Methods and assays for detecting guanylate cyclase activity |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1616965A1 (en) |
JP (1) | JP2008506371A (en) |
KR (1) | KR20070033428A (en) |
CN (1) | CN1985003A (en) |
AU (1) | AU2005263396A1 (en) |
CA (1) | CA2573357A1 (en) |
HR (1) | HRP20070011A2 (en) |
IL (1) | IL180666A0 (en) |
IS (1) | IS8590A (en) |
RU (1) | RU2007101290A (en) |
WO (1) | WO2006007937A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006038942A1 (en) * | 2006-08-18 | 2008-02-21 | Bayer Healthcare Ag | Method of identifying nitric oxide modulators |
AU2011242527B2 (en) * | 2010-04-23 | 2016-05-19 | University Of Florida Research Foundation, Inc. | rAAV-guanylate cyclase compositions and methods for treating Leber's congenital amaurosis-1 (LCA1) |
SG185777A1 (en) * | 2010-05-27 | 2012-12-28 | Merck Sharp & Dohme | Soluble guanylate cyclase activators |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783402A (en) * | 1991-10-01 | 1998-07-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of identifying ligands and anatgonists of G-protein coupled receptor |
EP0863214A2 (en) * | 1997-02-25 | 1998-09-09 | Smithkline Beecham Corporation | Reporter gene construct for measuring G protein coupled receptor activation |
US6221617B1 (en) * | 1996-12-06 | 2001-04-24 | Julie Heinrich | Bioassay for growth hormone releasing hormone |
-
2004
- 2004-07-16 EP EP04016774A patent/EP1616965A1/en not_active Withdrawn
-
2005
- 2005-06-27 CA CA002573357A patent/CA2573357A1/en not_active Abandoned
- 2005-06-27 AU AU2005263396A patent/AU2005263396A1/en not_active Abandoned
- 2005-06-27 CN CNA2005800234766A patent/CN1985003A/en active Pending
- 2005-06-27 RU RU2007101290/13A patent/RU2007101290A/en not_active Application Discontinuation
- 2005-06-27 WO PCT/EP2005/006887 patent/WO2006007937A1/en active Application Filing
- 2005-06-27 JP JP2007520697A patent/JP2008506371A/en active Pending
- 2005-06-27 KR KR1020077000872A patent/KR20070033428A/en not_active Application Discontinuation
-
2007
- 2007-01-11 IL IL180666A patent/IL180666A0/en unknown
- 2007-01-12 IS IS8590A patent/IS8590A/en unknown
- 2007-01-12 HR HR20070011A patent/HRP20070011A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783402A (en) * | 1991-10-01 | 1998-07-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of identifying ligands and anatgonists of G-protein coupled receptor |
US6221617B1 (en) * | 1996-12-06 | 2001-04-24 | Julie Heinrich | Bioassay for growth hormone releasing hormone |
EP0863214A2 (en) * | 1997-02-25 | 1998-09-09 | Smithkline Beecham Corporation | Reporter gene construct for measuring G protein coupled receptor activation |
Non-Patent Citations (4)
Title |
---|
BEUVE A: "Conversion of a Guanylyl Cyclase to an Adenylyl Cyclase", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 19, no. 4, December 1999 (1999-12-01), pages 545 - 550, XP004466856, ISSN: 1046-2023 * |
CHEN W ET AL: "A COLORIMETRIC ASSAY FOR MEASURING ACTIVATION OF GS-AND GQ-COUPLED SIGNALING PATHWAYS", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 226, 1995, pages 349 - 354, XP002051981, ISSN: 0003-2697 * |
FITZGERALD LAURA RYDELEK ET AL: "Measurement of responses from Gi-, Gs-, or Gq-coupled receptors by a multiple response element/cAMP response element-directed reporter assay", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 275, no. 1, 1 November 1999 (1999-11-01), pages 54 - 61, XP002320214, ISSN: 0003-2697 * |
SUNAHARA ROGER K ET AL: "Exchange of substrate and inhibitor specificities between adenylyl and guanylyl cyclases", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 26, 26 June 1998 (1998-06-26), pages 16332 - 16338, XP002325858, ISSN: 0021-9258 * |
Also Published As
Publication number | Publication date |
---|---|
AU2005263396A1 (en) | 2006-01-26 |
HRP20070011A2 (en) | 2007-04-30 |
RU2007101290A (en) | 2008-07-20 |
EP1616965A1 (en) | 2006-01-18 |
CA2573357A1 (en) | 2006-01-26 |
JP2008506371A (en) | 2008-03-06 |
IL180666A0 (en) | 2007-06-03 |
IS8590A (en) | 2007-01-12 |
KR20070033428A (en) | 2007-03-26 |
CN1985003A (en) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Beadling et al. | Interleukin‐2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. | |
JPH09500023A (en) | Identification of ligands by selective amplification of cells transfected with the receptor | |
Cox et al. | Regulation and functional characterization of a rat recombinant dopamine D3 receptor | |
Verzi et al. | N-twist, an evolutionarily conserved bHLH protein expressed in the developing CNS, functions as a transcriptional inhibitor | |
AU736899B2 (en) | Co-expression of Gia protein and Gi protein coupled receptor to enhance signal transduction responses | |
WO2014142984A1 (en) | Coincidence reporter gene system | |
WO2006007937A1 (en) | Methods and assays for detecting guanylate cyclase activity | |
RU2139936C1 (en) | Method of determining modulation effect of substance on interleukin-5 receptor-linked signal-transmission route in human or animal cell | |
CA2506619A1 (en) | Cell lines and host nucleic acid sequences related to infectious disease | |
Fujie et al. | Nitric oxide synthase and soluble guanylyl cyclase underlying the modulation of electrical oscillations in a central olfactory organ | |
JP2003534765A (en) | Isolated VSHK-1 receptor polypeptide and methods of using the same | |
Kanasaki et al. | cAMP responsive element-mediated regulation of the gene transcription of the alpha 1B adrenergic receptor by thyrotropin. | |
JP3643288B2 (en) | G protein-coupled receptor ligand screening method and G protein-coupled receptor expression cloning method | |
JPH119282A (en) | Melatonin receptor expression cell and its use | |
US20020164754A1 (en) | Compositions and methods for treatment of Toxoplasma gondii and other apicomplexans | |
JP2005118050A (en) | Screening method of g protein conjugating receptor ligand and expression cloning method of g protein conjugating receptor | |
MacDonald | Exploring the Pharmacophore of Novel Synthetic Peptide Activators of type I-alpha cGMP-Dependent Protein Kinase | |
JP4400183B2 (en) | Mutant estrogen receptor α and its gene | |
JP2002045188A (en) | Dioxin receptor gene and its use | |
US20020119440A1 (en) | Peripheral nerve type sodium channels | |
JP2000354494A (en) | Dioxin receptor gene and its utilization | |
JP2004254601A (en) | Variant androgen receptor and cell for evaluating its activity | |
JP2004008140A (en) | Variant androgen receptor and cell for evaluating its activity | |
JP2004008141A (en) | Variant androgen receptor and cell for evaluating its activity | |
JP2001078782A (en) | Dioxin receptor gene and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2573357 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 180666 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20070011A Country of ref document: HR Ref document number: 2007101290 Country of ref document: RU Ref document number: 200700360 Country of ref document: ZA Ref document number: 200580023476.6 Country of ref document: CN Ref document number: 1020077000872 Country of ref document: KR Ref document number: 2007520697 Country of ref document: JP Ref document number: 2005263396 Country of ref document: AU Ref document number: 162/KOLNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005263396 Country of ref document: AU Date of ref document: 20050627 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005263396 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020077000872 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |